Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
First in human, multicenter, non-randomized, open-label trial has expanded to three sites and is actively recruitingSAN FRANCISCO and SAN DIEGO,...